MX343269B - Procesos de cultivo celular. - Google Patents

Procesos de cultivo celular.

Info

Publication number
MX343269B
MX343269B MX2015014311A MX2015014311A MX343269B MX 343269 B MX343269 B MX 343269B MX 2015014311 A MX2015014311 A MX 2015014311A MX 2015014311 A MX2015014311 A MX 2015014311A MX 343269 B MX343269 B MX 343269B
Authority
MX
Mexico
Prior art keywords
cell culture
culture processes
urin
adamts
cho
Prior art date
Application number
MX2015014311A
Other languages
English (en)
Inventor
Giovagnoli Andre
Roy Sylvain
Ducros Veronique
Charlot Virginie
Stauffer Yves-Olivier
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX343269B publication Critical patent/MX343269B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a cultivo de células de mamífero que secretan proteína heteróloga, tal como células CHO ó BHK células, a una temperatura de 35.1°C a 36.50°C y/o en un pH de 7.15 a 7.20 y/o en una concentración de CO2 disuelto al 10% o menor. Las proteínas heterólogas preferidas son el Factor VIII, ADAMTS-13, furina o el Factor VIl.
MX2015014311A 2007-12-27 2008-12-22 Procesos de cultivo celular. MX343269B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932807P 2007-12-27 2007-12-27
PCT/US2008/088036 WO2009086309A2 (en) 2007-12-27 2008-12-22 Cell culture processes

Publications (1)

Publication Number Publication Date
MX343269B true MX343269B (es) 2016-10-31

Family

ID=40350258

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003366A MX343271B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.
MX2015014311A MX343269B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014003366A MX343271B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.

Country Status (21)

Country Link
US (2) US9359629B2 (es)
EP (4) EP2574676B1 (es)
JP (3) JP5727790B2 (es)
KR (4) KR101798813B1 (es)
CN (2) CN106222220A (es)
AR (2) AR069956A1 (es)
AU (1) AU2008345231B2 (es)
BR (1) BR122019022434B8 (es)
CA (1) CA2709890A1 (es)
DK (3) DK2574677T3 (es)
ES (3) ES2649094T3 (es)
HK (1) HK1246827A1 (es)
HR (3) HRP20171375T1 (es)
HU (2) HUE036712T2 (es)
MX (2) MX343271B (es)
NZ (1) NZ586250A (es)
PL (3) PL2574676T3 (es)
PT (3) PT2235197T (es)
SG (2) SG10201503304RA (es)
SI (3) SI2235197T1 (es)
WO (1) WO2009086309A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161866A (en) 2006-09-13 2017-05-15 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CA2769361A1 (en) 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
BR112013000515B1 (pt) 2010-07-08 2021-11-03 Takeda Pharmaceutical Company Limited Método para produzir uma composição de fator von willebrand recombinante (rvwf)
WO2012122611A1 (en) * 2011-03-11 2012-09-20 Universidade De São Paulo - Usp Method for the production of recombinant human factor viii
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
KR20150026024A (ko) * 2013-08-30 2015-03-11 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX2016012288A (es) 2014-03-25 2017-01-23 Genentech Inc Metodos para preparar un poloxamero para usar en medio de cultivo celular.
PE20161326A1 (es) * 2014-04-10 2016-12-11 Bayer Healthcare Llc Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular
EP3152318A1 (en) * 2014-06-03 2017-04-12 Lupin Limited Cell culture process for producing a protein
SG10202113019XA (en) 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
EP3298036B1 (en) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
CN109952370B (zh) * 2016-10-19 2023-09-08 豪夫迈·罗氏有限公司 用于产生免疫缀合物的方法
CN114657118B (zh) * 2021-12-31 2023-12-01 广州齐志生物工程设备有限公司 一种2bs细胞在生物反应器内的多倍放大方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4921792A (en) * 1987-11-27 1990-05-01 Miles Inc. Continuous cell dispersion, cultivation and substance recovery process
JPH0787799B2 (ja) * 1988-03-30 1995-09-27 森永製菓株式会社 モノクローナル抗体生産増強法
US6100050A (en) 1989-08-17 2000-08-08 Dade Behring Ag Factor VIII:Ca chromogenic assay
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2096418C (en) 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
EP0575464B1 (en) 1991-02-28 2004-08-11 Zymogenetics, Inc. Modified factor vii
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AU1333797A (en) * 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
WO1998000521A1 (fr) * 1996-06-28 1998-01-08 The Green Cross Corporation Milieux exempts de serum, methode de culture de cellules d'origine animale, et procede de production de substances physiologiquement actives
US5854021A (en) 1997-02-28 1998-12-29 Bayer Corporation Enhance protein production method
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
SE518174C2 (sv) * 1999-11-16 2002-09-03 Appliedsensor Sweden Ab Detektionsförfarande av oönskad mikrobiell infektion i animaliecellodling
ES2325877T3 (es) 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
CA2441580A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
JP2003047461A (ja) * 2001-07-31 2003-02-18 Astec:Kk アパタイトシ−トを用いた細胞の高密度細胞培養法及び培養装置、細胞培養モジュール
PT1451290E (pt) * 2001-08-31 2011-03-09 Bayer Schering Pharma Ag Uma unidade e um processo para levar a cabo a fermentação com elevada densidade celular
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
CN1309825C (zh) * 2001-10-02 2007-04-11 诺和诺德医疗保健公司 在真核细胞中生产重组蛋白的方法
EP1451315B1 (en) 2001-11-02 2014-05-21 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
US20030119723A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
EP1520008B1 (en) * 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
WO2004092218A1 (ja) * 2003-04-17 2004-10-28 Mitsubishi Pharma Corporation 組換えアンチトロンビンの製造方法
AU2005229359C1 (en) * 2004-03-05 2011-07-28 Patheon Holdings I B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
JP5523674B2 (ja) * 2005-02-11 2014-06-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
PL2522717T3 (pl) * 2006-01-04 2014-08-29 Baxalta Inc Pożywki do hodowli komórkowych wolne od oligopeptydów
DK2157177T3 (da) 2007-05-22 2013-06-24 Baxter Int Fremgangsmåde til præparativ oprensning af humant furin

Also Published As

Publication number Publication date
EP2574676B1 (en) 2017-08-30
PL2574676T3 (pl) 2017-12-29
CN101910408A (zh) 2010-12-08
SI2574677T1 (sl) 2017-11-30
PL2235197T3 (pl) 2018-01-31
PT2574677T (pt) 2017-10-19
JP2014100148A (ja) 2014-06-05
HRP20171374T1 (hr) 2017-12-29
WO2009086309A2 (en) 2009-07-09
PT2235197T (pt) 2017-10-11
HUE036496T2 (hu) 2018-07-30
SG187397A1 (en) 2013-02-28
US20090176269A1 (en) 2009-07-09
SI2235197T1 (sl) 2017-10-30
EP2574676A1 (en) 2013-04-03
KR20100097752A (ko) 2010-09-03
EP2574677A1 (en) 2013-04-03
BR122019022434B1 (pt) 2020-11-03
JP5890854B2 (ja) 2016-03-22
KR101818411B1 (ko) 2018-01-12
ES2649094T3 (es) 2018-01-10
EP3255152A1 (en) 2017-12-13
HRP20171495T1 (hr) 2018-01-26
SG10201503304RA (en) 2015-06-29
BRPI0821481A2 (pt) 2014-11-04
KR20160112025A (ko) 2016-09-27
CA2709890A1 (en) 2009-07-09
NZ586250A (en) 2012-11-30
CN106222220A (zh) 2016-12-14
AU2008345231A1 (en) 2009-07-09
PT2574676T (pt) 2017-10-11
WO2009086309A3 (en) 2009-10-01
HUE036712T2 (hu) 2018-07-30
KR20180005287A (ko) 2018-01-15
DK2574676T3 (en) 2017-10-09
EP2235197A2 (en) 2010-10-06
EP2574677B1 (en) 2017-09-13
DK2235197T3 (en) 2017-10-09
SI2574676T1 (sl) 2017-10-30
AU2008345231B2 (en) 2014-09-11
KR20170126514A (ko) 2017-11-17
US20160244506A1 (en) 2016-08-25
JP2011507551A (ja) 2011-03-10
EP2235197B1 (en) 2017-07-26
JP2016013140A (ja) 2016-01-28
AR110864A2 (es) 2019-05-08
KR101659458B1 (ko) 2016-09-23
KR101798813B1 (ko) 2017-11-16
JP5727790B2 (ja) 2015-06-03
ES2647294T3 (es) 2017-12-20
HRP20171375T1 (hr) 2017-12-15
ES2644089T3 (es) 2017-11-27
BR122019022434B8 (pt) 2021-07-27
US9359629B2 (en) 2016-06-07
DK2574677T3 (da) 2017-11-06
MX343271B (es) 2016-10-31
AR069956A1 (es) 2010-03-03
HK1246827A1 (zh) 2018-09-14
PL2574677T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
MX343271B (es) Procesos de cultivo celular.
AU2019268194A1 (en) Cell culture system
DE602005002829D1 (de) Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
GB2446525A (en) Stem cell culture medium and method
TW200636068A (en) A method of culturing a cell and use of the same
UA92157C2 (ru) Способ продуцирования гормона роста
CL2011001926A1 (es) Biorreactor para el cultivo de celulas de mamiferos donde dicho biorreactor posee un volumen de al menos 4000 l y al menos un impulsor superior y al menos un impulsor de fondo, donde el impulsor superior es un impulsor de hidroplano; metodo de cultivo; sistema de bioreactor.
MY160694A (en) Materials and methods for efficent succinate and malate production
MX2009011805A (es) Mejora de las concentraciones de polipeptido del factor viii en cultivos celulares.
MX2007002380A (es) Produccion de polipeptidos.
WO2011133902A3 (en) Cell culture medium comprising small peptides
CL2008001156A1 (es) Metodo para producir una proteina de fusion tnfr en un cultivo celular que comprende cultivar celulas de mamifero que contienen un gen que codifica la proteina de fusion en un medio de cultivo de celulas que comprende un compuesto anti-envejecimiento.
MX2007007040A (es) Proceso para el control de produccion de productos quimicos finos.
WO2008135498A3 (en) Prevention of protein degradation in mammalian cell cultures
DK1623023T3 (da) Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
IL190322A0 (en) Nutrient medium for the cultivation of a cell culture
MX2010002426A (es) Agente para promover la adhesion de las celulas del endotelio corneal.
ATE452664T1 (de) Verfahren und vorrichtung zum züchten von zellen
GB0702261D0 (en) No title
MY146352A (en) Adipose derived adult stem cells in hepatic regeneration
ATE336567T1 (de) Zellkulturmedium
NZ595833A (en) Method of producing a lipolytic enzyme
PT2401383E (pt) Métodos para seleccionar células eucarióticas que expressam uma proteína heteróloga
WO2009061905A8 (en) Methods of measuring cell viability without using control cells
GB2450599A (en) Automated culture of stem cells